Angry investors let ‘er rip at Dendreon (DNDN) leadership at the Provenge-maker’s annual meeting on Wednesday. And with good reason: stock price decreased 82 percent over the last year. “The long-term future for Provenge is bright,” countered CEO John Johnson, explaining the potential for a partner to help market the drug in Europe. The same day, shares soared after Summer Street initiated the stock with a buy rating. But let’s not get too excited here – Provenge still has JNJ’s Zytiga and Medivation’s up-and-coming enzalutamide to contend with.
EMRs + mergers = busy hospital CIOs. Increasing hospital M&A activity, which requires merging dozens of billing and procurement systems, combined with hospitals’ move to digital health records, can make things pretty complicated, as this WSJ column points out.
CellScope, a Rock Health startup with a device that connects to the iPhone with the intention of enabling remote diagnosis of ear infection, raised $1 million this week.
As the result of a five-year, $173 million NIH initiative called the Human Microbiome Project, scientists produced the first comprehensive genetic map of the microbes that live in a healthy body. A better understanding of bacteria and organisms in the body could lead to new advances in the diagnosis and treatment of disease.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author
